Preventing microalbuminuria in patients with type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 2, 2007, Pages 100-110

  Jermendy, György ^a   Ruggenenti, Piero ^b  

^a BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

ACE inhibitors; Antihypertensive treatment; Cardiovascular complications; Diabetic nephropathy; Microalbuminuria; Type 2 diabetes

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LOSARTAN; METOPROLOL TARTRATE; NIFEDIPINE; NISOLDIPINE; ORAL ANTIDIABETIC AGENT; PLACEBO; RAMIPRIL; SIMVASTATIN; TRANDOLAPRIL; VERAPAMIL;

ANEMIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DRUG POTENTIATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HOLISTIC CARE; HUMAN; HYPERTENSION; INSULIN TREATMENT; LIFE EXPECTANCY; META ANALYSIS; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN INTAKE; PUBLIC HEALTH; QUALITY OF LIFE; RENAL PROTECTION; REVIEW; SECONDARY PREVENTION; SMOKING CESSATION; SYSTEMATIC REVIEW; URINARY EXCRETION;

ALBUMINURIA; ANEMIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET, PROTEIN-RESTRICTED; DISEASE PROGRESSION; HUMANS; SMOKING CESSATION;

EID: 33847230968     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.693     Document Type: Review

References (93)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the International diabetes federation consensus workshop. Diabetes Care 2004; 27: 1798-1811.
3. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290: 1884-1890.
4. O'Brien JA, Shompe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998; 21: 1122-1128.
5. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002; 25:476-481.
6. Williams R, Van Gaal L, Lucioni C. CODE-2 advisory board. Assessing the impact of complications on the costs of type 2 diabetes. Diabetologia 2002; 45: S13-S17.
7. Ritz E, Stefanski A. Diabetic nephropathy in type 2 diabetes. Am J Kidney Dis 1996; 27: 167-194.
8. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.
9. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808.
10. Ismail N, Cornell S. Epidemiology of type 2 diabetes and diabetic nephropathy in different ethnicities. In Nephropathy in Type 2 Diabetes, Ritz E, Rychlik I (eds). Oxford University Press: Oxford, 1999; 11-24.
11. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004; 92: S2-S6.
12. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254: 45-66.
13. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-2105.
14. Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-249.
15. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
16. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-906.
17. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
18. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
19. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-35.
20. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46: 33-37.
21. Forman JP, Brenner BM. 'Hypertension' and 'microalbuminuria': the bell tolls for thee. Kidney Int 2006; 69: 22-28.
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
23. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, on behalf of the UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
24. Bruno G, Merletti F, Biggeri A, et al. Progression to overt nephropathy in type 2 diabetes. The Casale Monferrato Study. Diabetes Care 2003; 26: 2150-2155.
25. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145-1151.
26. Ruggenenti P, Remuzzi G. The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. Curr Opin Nephrol Hypertens 1997; 6: 141-145.
27. Farkas K, Noll E, Jermendy G. Prevalence of micro- and macroalbuminuria in Hungarian diabetic patients at primary health care setting. Diabetes Nutr Metab 1996; 9: 337-338.
28. American Diabetes Association. Clinical practice recommendations 2000. Diabetic nephropathy. Diabetes Care 2000; 23(Suppl 1): S69-S72.
29. Phillipou G, Phillips PJ. Variability of urinary albumin excretion in patients with microalbuminuria. Diabetes Care 1994; 17: 425-427.
30. Jermendy G, Farkas K, Nádas J, Daróczy A, Péterfai E. Practical aspects of measuring microalbuminuria in diabetic patients. Diabetes Nutr Metab 2001; 14: 195-200.
31. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Morrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabet Med 1984; 1: 17-19.
32. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
33. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
34. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
35. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226.
36. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005; 109: 143-159.
37. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and classification of diabetes mellitus. Report of a WHO consultation. Geneve, 1999.
38. Mann JF, Gernstein HC, Yi QL, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003; 42: 936-942.
39. Bruno G, Bigger A, Merletti F, et al. Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes. A 10-year prospective study. Diabetes Care 2003; 26: 2353-2358.
40. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317:703-713.
41. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713-720.
42. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction. Br Med J 1998; 317: 693-694.
43. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
44. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
45. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
46. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl 2): B21-B29.
47. The Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
48. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001; 60: 2041-2055.
49. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
50. Ravid M, Brosh D, Levi Z, Bar-Davan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982-988.
51. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222.
52. Crepaldi G, Carraro A, Brocco E, et al. Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol 1995; 32: 203-208.
53. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
54. Baba S, J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191-201.
55. BENEDICT Group. The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT): design and baseline characteristics. Control Clin Trials 2003; 24: 442-461.
56. Ruggenenti P, Sassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
57. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46: 1309-1315.
58. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
59. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
60. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of reninangiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 99: S57-S65.
61. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 3081-3091.
62. Strippoli G, Craig M, Craig J. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2005; CDO04136.
63. Strippoli GFM, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828.
64. Chuahirun T, Simoni J, Hudson C, et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004; 327: 57-67.
65. Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J. Steering committee of the swedish national diabetes register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes-data from the National Diabetes Register in Sweden. Diabetes Metab 2004; 30: 261-268.
66. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998-1004.
67. Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuria type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891-1895.
68. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
69. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
70. Wanner C, Krane V, Maärz W, et al. For the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
71. Atthobari J, Brantsma AH, Gansevoort RT, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21: 3106-3114.
72. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016.
73. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
74. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results form the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-493.
75. Ritz E. Managing anaemia and diabetes: a future challenge for nephrologists. Nephrol Dial Transplant 2005; 20: Suppl 6: 21-25.
76. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
77. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
78. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
79. Gross JL, Azevedo MJde, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176.
80. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 2006; 49: 11-19.
81. ESH-ESC Guidelines Committee. 2003 Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
82. Hansson L, Zanchetti A, Carruthers S, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
83. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study, BMJ 2000; 321: 1440-1444.
84. Campbell RC, Ruggenenti P, Remuzzi G. Proteinuria in diabetic nephropathy: treatment and evolution. Curr Diab Rep 2003, 3: 497-504.
85. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100.
86. Jacobsen P, Andersen S, Rossing K, Hansen KH, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1019-1024.
87. Bakris G, Weir MR, DeQuatro V, McMahon FG. Effects of an ACE inhibitor/ calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-1289.
88. Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, Rodriguez-Lopez L, Lozano-Nuevo JJ, Gomez-Harper CT. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004; 27: 1688-1691.
89. Vogt L, Navis G, de Zeeuw D. Renoprotection: a matter of blood pressure reduction or agent-characteristics? J Am Soc Nephrol 2002; 13: S202-S207.
90. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
91. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
92. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
93. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784-2788.